{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T14:18:04Z","timestamp":1782569884606,"version":"3.54.5"},"reference-count":31,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2014,9,18]],"date-time":"2014-09-18T00:00:00Z","timestamp":1410998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["1UL1 TR001102-01"],"award-info":[{"award-number":["1UL1 TR001102-01"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Trust Family and Michael Brigham funds for Kidney Cancer Research"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2015,1,15]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>VEGF signaling pathway inhibitor (anti\u2010VEGF) therapy is associated with hypertension, but little is known about predisposing clinical characteristics. This study describes the real\u2010world association between baseline clinical characteristics, blood pressure (BP) response, and survival in patients prescribed anti\u2010VEGF therapies.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Clinical data from Partners HealthCare in Massachusetts was obtained from adults treated with anti\u2010VEGF therapies (2002\u20102013). Treatment\u2010induced hypertensive response was defined as worsening of preexisting hypertension or new diagnosis of hypertension (if no prior hypertension history).<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Data from 1120 patients with renal cell carcinoma (32.2%), hepatocellular carcinoma (11.6%), gastrointestinal stromal tumors (12.5%), and other sarcomas (15.3%) were analyzed. Most patients received sunitinib (52%), sorafenib (25.9%), or pazopanib (18%). A treatment\u2010induced hypertensive response was identified in 49.7% of treated patients. Preexisting hypertension, present in 65.4%, was an independent risk factor for BP elevation (odds ratio [OR], 1.56; 95% confidence interval [CI], 1.27\u20101.92); other risk factors included age \u226560 years (OR, 1.26; 95% CI, 1.06\u20101.52), and body mass index (BMI) \u226525 kg\/m<jats:sup>2<\/jats:sup> (OR, 1.26; 95% CI, 1.04\u20101.53). Race, sex, anti\u2010VEGF therapy prescribed, and baseline antihypertensive class were not significant risk factors. The absolute observed mean increase in BP was 21 mm Hg (systolic)\/15 mm Hg (diastolic), both in patients with and without preexisting hypertension. The development of hypertension predicted improved survival (hazard ratio, 0.76; 95% CI, 0.65\u20100.89).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Preexisting hypertension, age, and BMI identify patients at risk for significant anti\u2010VEGF therapy\u2010induced BP elevation. Hypertension appears to be a clinical biomarker of efficacy of anti\u2010VEGF therapies in a broad range of malignancies. <jats:bold><jats:italic>Cancer<\/jats:italic> 2015;121:311\u20139<\/jats:bold>. \u00a9 <jats:italic>2014 American Cancer Society<\/jats:italic>.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.28972","type":"journal-article","created":{"date-parts":[[2014,9,18]],"date-time":"2014-09-18T11:23:08Z","timestamp":1411039388000},"page":"311-319","source":"Crossref","is-referenced-by-count":185,"title":["Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway"],"prefix":"10.1002","volume":"121","author":[{"given":"Ole\u2010Petter R.","family":"Hamnvik","sequence":"first","affiliation":[{"name":"Brigham and Women's Hospital Division of Endocrinology, Diabetes and Hypertension Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[{"name":"Dana\u2010Farber Cancer Institute Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Turchin","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital Division of Endocrinology, Diabetes and Hypertension Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana R.","family":"McKay","sequence":"additional","affiliation":[{"name":"Dana\u2010Farber Cancer Institute Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lipika","family":"Goyal","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Davis","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital Division of Endocrinology, Diabetes and Hypertension Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina D.","family":"Kaymakcalan","sequence":"additional","affiliation":[{"name":"Dana Farber Cancer Institute Pharmacy Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S.","family":"Williams","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital Division of Endocrinology, Diabetes and Hypertension Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,9,18]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006577"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70003-2"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/02841860802314720"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04417.x"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-012-2025-5"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12149"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jch.12052"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-011-0201-x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcm.2012.09.008"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr128"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2806"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26491"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.19.2560"},{"key":"e_1_2_7_15_1","unstructured":"National Cancer Institute.Common Terminology Criteria for Adverse Events v4.0: NCI NIH DHHS May 29 2009."},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/jhh.2013.30"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01953.x"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.2273"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0058"},{"issue":"4","key":"e_1_2_7_20_1","article-title":"Clinicopathologic factors associated with the development of sunitinib induced hypertension (HTN) in patients (pts) with metastatic renal cell carcinoma (mRCC)","volume":"32","author":"Neiman V","year":"2014","journal-title":"J Clin Oncol."},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1893"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.67137.x"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2010.11.013"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708857"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.1293"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69446-4"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.11.056"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2008.09.007"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27639"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt310"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.04.019"},{"issue":"4","key":"e_1_2_7_32_1","article-title":"Impact of angiotensin system inhibitors (ASI) on outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC): Results from a pooled clinical trials database","volume":"32","author":"McKay RR","year":"2014","journal-title":"J Clin Oncol"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.28972","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.28972","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.28972","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:52:00Z","timestamp":1760298720000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.28972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,18]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,1,15]]}},"alternative-id":["10.1002\/cncr.28972"],"URL":"https:\/\/doi.org\/10.1002\/cncr.28972","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,18]]}}}